Good morning, everyone, and how are you today? We are doing just fine, thank you, as a hazy sky is giving way to a bit of sunshine and a soothing quiet has descended on the Pharmalot campus. Of course, we are busy as ever, foraging for interesting items. Summer may be upon us, but the world continues to spin, even if the ride is a bit rocky at times. So please join us for a cup of stimulation to restore some equilibrium. Meanwhile, here are a few tidbits for you. Hope your day is simply smashing and do drop us a line when you come across something confidential …
A group of Takeda Pharmaceutical (TKPYY) shareholders who are trying to block the $62 billion acquisition of Shire (SHPG) failed to get a proposal passed at the drug maker’s annual general meeting, Reuters reports. The proposal — to require advance shareholder approval for large acquisitions — received 10 percent of votes. But the 130-member group formed by ex-Takeda employees is also working to persuade one-third of shareholders to vote against a company proposal at an upcoming Takeda shareholder meeting to approve an issue of new stock to help fund the Shire deal.
About the Author Reprints
